Although Hsp90 inhibitors intercept multiple oncogenic and resistance pathways at once18,24, their clinical activity to date has been restricted to the cancers driven by the most sensitive Hsp90 clients, e.g., HER2-positive breast cancer25–27 and EML4-ALK-positive non-small-cell lung cancer28,29. Here, ERBB2 is linked to cancer.